ID   DYR_HUMAN               Reviewed;         187 AA.
AC   P00374; B4DDD2; Q14130; Q6IRW8;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 191.
DE   RecName: Full=Dihydrofolate reductase;
DE            EC=1.5.1.3;
GN   Name=DHFR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6323448;
RA   Chen M.-J., Shimada T., Moulton A.D., Cline A., Humphries R.K.,
RA   Maizel J., Nienhuis A.W.;
RT   "The functional human dihydrofolate reductase gene.";
RL   J. Biol. Chem. 259:3933-3943(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=6687716; DOI=10.1016/0378-1119(83)90147-6;
RA   Masters J.N., Attardi G.;
RT   "The nucleotide sequence of the cDNA coding for the human dihydrofolic
RT   acid reductase.";
RL   Gene 21:59-63(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6235374; DOI=10.1016/0022-2836(84)90419-4;
RA   Yang J.K., Masters J.N., Attardi G.;
RT   "Human dihydrofolate reductase gene organization. Extensive
RT   conservation of the G + C-rich 5' non-coding sequence and strong
RT   intron size divergence from homologous mammalian genes.";
RL   J. Mol. Biol. 176:169-187(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY, AND VARIANT DHFRD PHE-80.
RX   PubMed=21310276; DOI=10.1016/j.ajhg.2011.01.004;
RA   Banka S., Blom H.J., Walter J., Aziz M., Urquhart J., Clouthier C.M.,
RA   Rice G.I., de Brouwer A.P., Hilton E., Vassallo G., Will A.,
RA   Smith D.E., Smulders Y.M., Wevers R.A., Steinfeld R., Heales S.,
RA   Crow Y.J., Pelletier J.N., Jones S., Newman W.G.;
RT   "Identification and characterization of an inborn error of metabolism
RT   caused by dihydrofolate reductase deficiency.";
RL   Am. J. Hum. Genet. 88:216-225(2011).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   CATALYTIC ACTIVITY, RNA-BINDING, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=21876184; DOI=10.1073/pnas.1103605108;
RA   McEntee G., Minguzzi S., O'Brien K., Ben Larbi N., Loscher C.,
RA   O'Fagain C., Parle-McDermott A.;
RT   "The former annotated human pseudogene dihydrofolate reductase-like 1
RT   (DHFRL1) is expressed and functional.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:15157-15162(2011).
RN   [10]
RP   FUNCTION.
RX   PubMed=21876188; DOI=10.1073/pnas.1103623108;
RA   Anderson D.D., Quintero C.M., Stover P.J.;
RT   "Identification of a de novo thymidylate biosynthesis pathway in
RT   mammalian mitochondria.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:15163-15168(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH FOLATE.
RX   PubMed=3383852; DOI=10.1111/j.1432-1033.1988.tb14108.x;
RA   Oefner C., D'Arcy A., Winkler F.K.;
RT   "Crystal structure of human dihydrofolate reductase complexed with
RT   folate.";
RL   Eur. J. Biochem. 174:377-385(1988).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEXES WITH FOLATE AND
RP   5-DEAZAFOLATE, AND SUBUNIT.
RX   PubMed=2248959; DOI=10.1021/bi00492a021;
RA   Davies J.F., Delcamp T.J., Prendergast N.J., Ashford V.A.,
RA   Freisheim J.H., Kraut J.;
RT   "Crystal structures of recombinant human dihydrofolate reductase
RT   complexed with folate and 5-deazafolate.";
RL   Biochemistry 29:9467-9479(1990).
RN   [13]
RP   STRUCTURE BY NMR.
RX   PubMed=1731871; DOI=10.1021/bi00116a031;
RA   Stockman B.J., Nirmala N.R., Wagner G., Delcamp T.J., Deyarman M.T.,
RA   Freisheim J.H.;
RT   "Sequence-specific 1H and 15N resonance assignments for human
RT   dihydrofolate reductase in solution.";
RL   Biochemistry 31:218-229(1992).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) IN COMPLEXES WITH NADPH;
RP   PIRITREXIM AND METOTHREXATE, AND MUTAGENESIS OF LEU-23.
RX   PubMed=7890613; DOI=10.1074/jbc.270.10.5057;
RA   Lewis W.S., Cody V., Galitsky N., Luft J.R., Pangborn W.,
RA   Chunduru S.K., Spencer H.T., Appleman J.R., Blakley R.L.;
RT   "Methotrexate-resistant variants of human dihydrofolate reductase with
RT   substitutions of leucine 22. Kinetics, crystallography, and potential
RT   as selectable markers.";
RL   J. Biol. Chem. 270:5057-5064(1995).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   PubMed=9374868; DOI=10.1021/bi971711l;
RA   Cody V., Galitsky N., Luft J.R., Pangborn W., Blakley R.L.,
RA   Gangjee A.;
RT   "Comparison of two independent crystal structures of human
RT   dihydrofolate reductase ternary complexes reduced with nicotinamide
RT   adenine dinucleotide phosphate and the very tight-binding inhibitor
RT   PT523.";
RL   Biochemistry 36:13897-13903(1997).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEXES WITH NADPH AND
RP   QUINAZOLINE INHIBITORS, AND CATALYTIC ACTIVITY.
RX   PubMed=9719595; DOI=10.1021/jm980081y;
RA   Gangjee A., Vidwans A.P., Vasudevan A., Queener S.F., Kisliuk R.L.,
RA   Cody V., Li R., Galitsky N., Luft J.R., Pangborn W.;
RT   "Structure-based design and synthesis of lipophilic 2,4-diamino-6-
RT   substituted quinazolines and their evaluation as inhibitors of
RT   dihydrofolate reductases and potential antitumor agents.";
RL   J. Med. Chem. 41:3426-3434(1998).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) IN COMPLEXES WITH NADP AND THE
RP   SYNTHETIC INHIBITORS SRI-9439 AND SRI-9662, FUNCTION, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=12096917; DOI=10.1016/S0022-2836(02)00469-2;
RA   Klon A.E., Heroux A., Ross L.J., Pathak V., Johnson C.A., Piper J.R.,
RA   Borhani D.W.;
RT   "Atomic structures of human dihydrofolate reductase complexed with
RT   NADPH and two lipophilic antifolates at 1.09 A and 1.05 A
RT   resolution.";
RL   J. Mol. Biol. 320:677-693(2002).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=12657784; DOI=10.1107/S0907444903001951;
RA   Cody V., Galitsky N., Luft J.R., Pangborn W., Gangjee A.;
RT   "Analysis of two polymorphic forms of a pyrido[2,3-d]pyrimidine N9-C10
RT   reversed-bridge antifolate binary complex with human dihydrofolate
RT   reductase.";
RL   Acta Crystallogr. D 59:654-661(2003).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=12925791; DOI=10.1107/S0907444903014963;
RA   Cody V., Luft J.R., Pangborn W., Gangjee A.;
RT   "Analysis of three crystal structure determinations of a 5-methyl-6-N-
RT   methylanilino pyridopyrimidine antifolate complex with human
RT   dihydrofolate reductase.";
RL   Acta Crystallogr. D 59:1603-1609(2003).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH NADPH AND
RP   INHIBITOR, MUTAGENESIS OF GLN-36 AND ASN-65, CATALYTIC ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15039552; DOI=10.1107/S0907444904002094;
RA   Cody V., Luft J.R., Pangborn W., Gangjee A., Queener S.F.;
RT   "Structure determination of tetrahydroquinazoline antifolates in
RT   complex with human and Pneumocystis carinii dihydrofolate reductase:
RT   correlations between enzyme selectivity and stereochemistry.";
RL   Acta Crystallogr. D 60:646-655(2004).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEXES WITH NADP AND
RP   METHOTREXATE, AND MUTAGENESIS OF LEU-23.
RX   PubMed=15681865; DOI=10.1107/S0907444904030422;
RA   Cody V., Luft J.R., Pangborn W.;
RT   "Understanding the role of Leu22 variants in methotrexate resistance:
RT   comparison of wild-type and Leu22Arg variant mouse and human
RT   dihydrofolate reductase ternary crystal complexes with methotrexate
RT   and NADPH.";
RL   Acta Crystallogr. D 61:147-155(2005).
RN   [22]
RP   STRUCTURE BY NMR IN COMPLEX WITH TRIMETHOPRIM AND NADPH.
RX   PubMed=16222560; DOI=10.1007/s10858-005-1475-z;
RA   Kovalevskaya N.V., Smurnyy Y.D., Polshakov V.I., Birdsall B.,
RA   Bradbury A.F., Frenkiel T., Feeney J.;
RT   "Solution structure of human dihydrofolate reductase in its complex
RT   with trimethoprim and NADPH.";
RL   J. Biomol. NMR 33:69-72(2005).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) IN COMPLEXES WITH NADP AND
RP   BORON-CONTAINING INHIBITORS, AND CATALYTIC ACTIVITY.
RX   PubMed=17569517; DOI=10.1021/jm0701977;
RA   Reynolds R.C., Campbell S.R., Fairchild R.G., Kisliuk R.L.,
RA   Micca P.L., Queener S.F., Riordan J.M., Sedwick W.D., Waud W.R.,
RA   Leung A.K., Dixon R.W., Suling W.J., Borhani D.W.;
RT   "Novel boron-containing, nonclassical antifolates: synthesis and
RT   preliminary biological and structural evaluation.";
RL   J. Med. Chem. 50:3283-3289(2007).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.23 ANGSTROMS) IN COMPLEXES WITH NADP AND THE
RP   SYNTHETIC INHIBITOR PY957, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF GLN-36 AND ASN-65.
RX   PubMed=19196009; DOI=10.1021/bi801960h;
RA   Cody V., Pace J., Makin J., Piraino J., Queener S.F., Rosowsky A.;
RT   "Correlations of inhibitor kinetics for Pneumocystis jirovecii and
RT   human dihydrofolate reductase with structural data for human active
RT   site mutant enzyme complexes.";
RL   Biochemistry 48:1702-1711(2009).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF MUTANT ARG-32/GLU-36 IN
RP   COMPLEX WITH METHOTREXATE AND NADP, MUTAGENESIS OF PHE-32 AND GLN-36,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=19478082; DOI=10.1074/jbc.M109.018010;
RA   Volpato J.P., Yachnin B.J., Blanchet J., Guerrero V., Poulin L.,
RA   Fossati E., Berghuis A.M., Pelletier J.N.;
RT   "Multiple conformers in active site of human dihydrofolate reductase
RT   F31R/Q35E double mutant suggest structural basis for methotrexate
RT   resistance.";
RL   J. Biol. Chem. 284:20079-20089(2009).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.24 ANGSTROMS) OF 1-187.
RX   PubMed=19719239; DOI=10.1021/jm900490a;
RA   Gangjee A., Li W., Kisliuk R.L., Cody V., Pace J., Piraino J.,
RA   Makin J.;
RT   "Design, synthesis, and X-ray crystal structure of classical and
RT   nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-
RT   d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase
RT   inhibitors and as potential antitumor agents.";
RL   J. Med. Chem. 52:4892-4902(2009).
RN   [27]
RP   VARIANT DHFRD VAL-153.
RX   PubMed=21310277; DOI=10.1016/j.ajhg.2011.01.007;
RA   Cario H., Smith D.E., Blom H., Blau N., Bode H., Holzmann K.,
RA   Pannicke U., Hopfner K.P., Rump E.M., Ayric Z., Kohne E.,
RA   Debatin K.M., Smulders Y., Schwarz K.;
RT   "Dihydrofolate reductase deficiency due to a homozygous DHFR mutation
RT   causes megaloblastic anemia and cerebral folate deficiency leading to
RT   severe neurologic disease.";
RL   Am. J. Hum. Genet. 88:226-231(2011).
CC   -!- FUNCTION: Key enzyme in folate metabolism. Contributes to the de
CC       novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an
CC       essential reaction for de novo glycine and purine synthesis, and
CC       for DNA precursor synthesis. Binds its own mRNA and that of DHFR2.
CC       {ECO:0000269|PubMed:12096917, ECO:0000269|PubMed:21876188}.
CC   -!- CATALYTIC ACTIVITY: 5,6,7,8-tetrahydrofolate + NADP(+) = 7,8-
CC       dihydrofolate + NADPH. {ECO:0000255|PROSITE-ProRule:PRU00660,
CC       ECO:0000269|PubMed:12096917, ECO:0000269|PubMed:15039552,
CC       ECO:0000269|PubMed:17569517, ECO:0000269|PubMed:19196009,
CC       ECO:0000269|PubMed:19478082, ECO:0000269|PubMed:21876184,
CC       ECO:0000269|PubMed:9719595}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.7 uM for dihydrofolate {ECO:0000269|PubMed:15039552,
CC         ECO:0000269|PubMed:19196009, ECO:0000269|PubMed:21876184};
CC         KM=4.0 uM for NADPH {ECO:0000269|PubMed:15039552,
CC         ECO:0000269|PubMed:19196009, ECO:0000269|PubMed:21876184};
CC   -!- PATHWAY: Cofactor biosynthesis; tetrahydrofolate biosynthesis;
CC       5,6,7,8-tetrahydrofolate from 7,8-dihydrofolate: step 1/1.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:12657784,
CC       ECO:0000269|PubMed:12925791, ECO:0000269|PubMed:15039552,
CC       ECO:0000269|PubMed:16222560, ECO:0000269|PubMed:19478082,
CC       ECO:0000269|PubMed:2248959, ECO:0000269|PubMed:3383852}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion
CC       {ECO:0000250|UniProtKB:P00375}. Cytoplasm
CC       {ECO:0000250|UniProtKB:P00375}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P00374-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P00374-2; Sequence=VSP_056352;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed in fetal and adult tissues,
CC       including throughout the fetal and adult brains and whole blood.
CC       Expression is higher in the adult brain than in the fetal brain.
CC       {ECO:0000269|PubMed:21310276}.
CC   -!- DISEASE: Megaloblastic anemia due to dihydrofolate reductase
CC       deficiency (DHFRD) [MIM:613839]: An inborn error of metabolism,
CC       characterized by megaloblastic anemia and/or pancytopenia, severe
CC       cerebral folate deficiency, and cerebral tetrahydrobiopterin
CC       deficiency. Clinical features include variable neurologic
CC       symptoms, ranging from severe developmental delay and generalized
CC       seizures in infancy, to childhood absence epilepsy with learning
CC       difficulties, to lack of symptoms. {ECO:0000269|PubMed:21310276,
CC       ECO:0000269|PubMed:21310277}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the dihydrofolate reductase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Dihydrofolate reductase entry;
CC       URL="https://en.wikipedia.org/wiki/Dihydrofolate_reductase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J00140; AAA58485.1; -; mRNA.
DR   EMBL; V00507; CAA23765.1; -; mRNA.
DR   EMBL; J00139; AAA58484.1; -; Genomic_DNA.
DR   EMBL; K01612; AAA58484.1; JOINED; Genomic_DNA.
DR   EMBL; K01613; AAA58484.1; JOINED; Genomic_DNA.
DR   EMBL; J00138; AAA58484.1; JOINED; Genomic_DNA.
DR   EMBL; K01614; AAA58484.1; JOINED; Genomic_DNA.
DR   EMBL; X00855; CAA25409.1; -; Genomic_DNA.
DR   EMBL; X00856; CAA25409.1; JOINED; Genomic_DNA.
DR   EMBL; X00857; CAA25409.1; JOINED; Genomic_DNA.
DR   EMBL; X00858; CAA25409.1; JOINED; Genomic_DNA.
DR   EMBL; X00859; CAA25409.1; JOINED; Genomic_DNA.
DR   EMBL; AK293146; BAG56693.1; -; mRNA.
DR   EMBL; AC008434; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010270; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000192; AAH00192.1; -; mRNA.
DR   EMBL; BC003584; AAH03584.2; -; mRNA.
DR   EMBL; BC070280; AAH70280.1; -; mRNA.
DR   EMBL; BC071996; AAH71996.1; -; mRNA.
DR   CCDS; CCDS47240.1; -. [P00374-1]
DR   CCDS; CCDS78028.1; -. [P00374-2]
DR   PIR; A22551; RDHUD.
DR   RefSeq; NP_000782.1; NM_000791.3. [P00374-1]
DR   RefSeq; NP_001277283.1; NM_001290354.1. [P00374-2]
DR   UniGene; Hs.592364; -.
DR   UniGene; Hs.648635; -.
DR   PDB; 1BOZ; X-ray; 2.10 A; A=2-187.
DR   PDB; 1DHF; X-ray; 2.30 A; A/B=2-187.
DR   PDB; 1DLR; X-ray; 2.30 A; A=2-187.
DR   PDB; 1DLS; X-ray; 2.30 A; A=2-187.
DR   PDB; 1DRF; X-ray; 2.00 A; A=2-187.
DR   PDB; 1HFP; X-ray; 2.10 A; A=2-187.
DR   PDB; 1HFQ; X-ray; 2.10 A; A=2-187.
DR   PDB; 1HFR; X-ray; 2.10 A; A=2-187.
DR   PDB; 1KMS; X-ray; 1.09 A; A=2-187.
DR   PDB; 1KMV; X-ray; 1.05 A; A=2-187.
DR   PDB; 1MVS; X-ray; 1.90 A; A=1-187.
DR   PDB; 1MVT; X-ray; 1.80 A; A=1-187.
DR   PDB; 1OHJ; X-ray; 2.50 A; A=2-187.
DR   PDB; 1OHK; X-ray; 2.50 A; A=2-187.
DR   PDB; 1PD8; X-ray; 2.10 A; A=2-187.
DR   PDB; 1PD9; X-ray; 2.20 A; A=2-187.
DR   PDB; 1PDB; X-ray; 2.20 A; A=2-187.
DR   PDB; 1S3U; X-ray; 2.50 A; A=2-187.
DR   PDB; 1S3V; X-ray; 1.80 A; A=2-187.
DR   PDB; 1S3W; X-ray; 1.90 A; A=2-187.
DR   PDB; 1U71; X-ray; 2.20 A; A=2-187.
DR   PDB; 1U72; X-ray; 1.90 A; A=2-187.
DR   PDB; 1YHO; NMR; -; A=2-187.
DR   PDB; 2C2S; X-ray; 1.40 A; A/B=2-187.
DR   PDB; 2C2T; X-ray; 1.50 A; A/B=2-187.
DR   PDB; 2DHF; X-ray; 2.30 A; A/B=2-187.
DR   PDB; 2W3A; X-ray; 1.50 A; A/B=1-187.
DR   PDB; 2W3B; X-ray; 1.27 A; A/B=1-187.
DR   PDB; 2W3M; X-ray; 1.60 A; A/B=1-187.
DR   PDB; 3EIG; X-ray; 1.70 A; A=2-187.
DR   PDB; 3F8Y; X-ray; 1.45 A; A=1-187.
DR   PDB; 3F8Z; X-ray; 2.01 A; A=1-187.
DR   PDB; 3F91; X-ray; 1.90 A; A=1-187.
DR   PDB; 3FS6; X-ray; 1.23 A; A=1-187.
DR   PDB; 3GHC; X-ray; 1.30 A; A=2-187.
DR   PDB; 3GHV; X-ray; 1.30 A; A=2-187.
DR   PDB; 3GHW; X-ray; 1.24 A; A=2-187.
DR   PDB; 3GI2; X-ray; 1.53 A; A=1-187.
DR   PDB; 3GYF; X-ray; 1.70 A; A=1-187.
DR   PDB; 3L3R; X-ray; 2.00 A; A=2-187.
DR   PDB; 3N0H; X-ray; 1.92 A; A=2-187.
DR   PDB; 3NTZ; X-ray; 1.35 A; A=2-187.
DR   PDB; 3NU0; X-ray; 1.35 A; A=2-187.
DR   PDB; 3NXO; X-ray; 1.35 A; A=2-187.
DR   PDB; 3NXR; X-ray; 1.35 A; A=2-187.
DR   PDB; 3NXT; X-ray; 1.70 A; A=2-187.
DR   PDB; 3NXV; X-ray; 1.90 A; A=2-187.
DR   PDB; 3NXX; X-ray; 1.35 A; A=2-187.
DR   PDB; 3NXY; X-ray; 1.90 A; A=2-187.
DR   PDB; 3NZD; X-ray; 1.80 A; A=2-187.
DR   PDB; 3OAF; X-ray; 1.70 A; A=2-187.
DR   PDB; 3S3V; X-ray; 1.53 A; A=2-187.
DR   PDB; 3S7A; X-ray; 1.80 A; A=2-187.
DR   PDB; 4DDR; X-ray; 2.05 A; A=2-187.
DR   PDB; 4G95; X-ray; 1.35 A; A=2-187.
DR   PDB; 4KAK; X-ray; 1.80 A; A/B=2-187.
DR   PDB; 4KBN; X-ray; 1.84 A; A/B=2-187.
DR   PDB; 4KD7; X-ray; 2.72 A; A/B=2-187.
DR   PDB; 4KEB; X-ray; 1.45 A; A/B=2-187.
DR   PDB; 4KFJ; X-ray; 1.76 A; A/B=2-187.
DR   PDB; 4M6J; X-ray; 1.20 A; A=1-187.
DR   PDB; 4M6K; X-ray; 1.40 A; A=1-187.
DR   PDB; 4M6L; X-ray; 1.70 A; A=1-187.
DR   PDB; 4QHV; X-ray; 1.61 A; A=2-187.
DR   PDB; 4QJC; X-ray; 1.62 A; A=2-187.
DR   PDB; 5HPB; X-ray; 1.65 A; A=2-187.
DR   PDB; 5HQY; X-ray; 1.46 A; A=2-187.
DR   PDB; 5HQZ; X-ray; 1.46 A; A=2-187.
DR   PDB; 5HSR; X-ray; 1.21 A; A=2-187.
DR   PDB; 5HSU; X-ray; 1.46 A; A=2-187.
DR   PDB; 5HT4; X-ray; 1.60 A; A=2-187.
DR   PDB; 5HT5; X-ray; 1.90 A; A=2-187.
DR   PDB; 5HUI; X-ray; 1.46 A; A=2-187.
DR   PDB; 5HVB; X-ray; 1.60 A; A=2-187.
DR   PDB; 5HVE; X-ray; 1.46 A; A=2-187.
DR   PDBsum; 1BOZ; -.
DR   PDBsum; 1DHF; -.
DR   PDBsum; 1DLR; -.
DR   PDBsum; 1DLS; -.
DR   PDBsum; 1DRF; -.
DR   PDBsum; 1HFP; -.
DR   PDBsum; 1HFQ; -.
DR   PDBsum; 1HFR; -.
DR   PDBsum; 1KMS; -.
DR   PDBsum; 1KMV; -.
DR   PDBsum; 1MVS; -.
DR   PDBsum; 1MVT; -.
DR   PDBsum; 1OHJ; -.
DR   PDBsum; 1OHK; -.
DR   PDBsum; 1PD8; -.
DR   PDBsum; 1PD9; -.
DR   PDBsum; 1PDB; -.
DR   PDBsum; 1S3U; -.
DR   PDBsum; 1S3V; -.
DR   PDBsum; 1S3W; -.
DR   PDBsum; 1U71; -.
DR   PDBsum; 1U72; -.
DR   PDBsum; 1YHO; -.
DR   PDBsum; 2C2S; -.
DR   PDBsum; 2C2T; -.
DR   PDBsum; 2DHF; -.
DR   PDBsum; 2W3A; -.
DR   PDBsum; 2W3B; -.
DR   PDBsum; 2W3M; -.
DR   PDBsum; 3EIG; -.
DR   PDBsum; 3F8Y; -.
DR   PDBsum; 3F8Z; -.
DR   PDBsum; 3F91; -.
DR   PDBsum; 3FS6; -.
DR   PDBsum; 3GHC; -.
DR   PDBsum; 3GHV; -.
DR   PDBsum; 3GHW; -.
DR   PDBsum; 3GI2; -.
DR   PDBsum; 3GYF; -.
DR   PDBsum; 3L3R; -.
DR   PDBsum; 3N0H; -.
DR   PDBsum; 3NTZ; -.
DR   PDBsum; 3NU0; -.
DR   PDBsum; 3NXO; -.
DR   PDBsum; 3NXR; -.
DR   PDBsum; 3NXT; -.
DR   PDBsum; 3NXV; -.
DR   PDBsum; 3NXX; -.
DR   PDBsum; 3NXY; -.
DR   PDBsum; 3NZD; -.
DR   PDBsum; 3OAF; -.
DR   PDBsum; 3S3V; -.
DR   PDBsum; 3S7A; -.
DR   PDBsum; 4DDR; -.
DR   PDBsum; 4G95; -.
DR   PDBsum; 4KAK; -.
DR   PDBsum; 4KBN; -.
DR   PDBsum; 4KD7; -.
DR   PDBsum; 4KEB; -.
DR   PDBsum; 4KFJ; -.
DR   PDBsum; 4M6J; -.
DR   PDBsum; 4M6K; -.
DR   PDBsum; 4M6L; -.
DR   PDBsum; 4QHV; -.
DR   PDBsum; 4QJC; -.
DR   PDBsum; 5HPB; -.
DR   PDBsum; 5HQY; -.
DR   PDBsum; 5HQZ; -.
DR   PDBsum; 5HSR; -.
DR   PDBsum; 5HSU; -.
DR   PDBsum; 5HT4; -.
DR   PDBsum; 5HT5; -.
DR   PDBsum; 5HUI; -.
DR   PDBsum; 5HVB; -.
DR   PDBsum; 5HVE; -.
DR   ProteinModelPortal; P00374; -.
DR   SMR; P00374; -.
DR   BioGrid; 108065; 10.
DR   IntAct; P00374; 3.
DR   MINT; MINT-5002355; -.
DR   STRING; 9606.ENSP00000396308; -.
DR   BindingDB; P00374; -.
DR   ChEMBL; CHEMBL202; -.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB08878; Aminopterin.
DR   DrugBank; DB03886; Biopterin.
DR   DrugBank; DB00798; Gentamicin.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00642; Pemetrexed.
DR   DrugBank; DB06813; Pralatrexate.
DR   DrugBank; DB01131; Proguanil.
DR   DrugBank; DB00205; Pyrimethamine.
DR   DrugBank; DB03351; Sri-9439.
DR   DrugBank; DB03060; Sri-9662.
DR   DrugBank; DB00440; Trimethoprim.
DR   DrugBank; DB01157; Trimetrexate.
DR   GuidetoPHARMACOLOGY; 2603; -.
DR   MoonProt; P00374; -.
DR   iPTMnet; P00374; -.
DR   PhosphoSitePlus; P00374; -.
DR   SwissPalm; P00374; -.
DR   BioMuta; DHFR; -.
DR   DMDM; 118992; -.
DR   UCD-2DPAGE; P00374; -.
DR   EPD; P00374; -.
DR   MaxQB; P00374; -.
DR   PaxDb; P00374; -.
DR   PeptideAtlas; P00374; -.
DR   PRIDE; P00374; -.
DR   DNASU; 1719; -.
DR   Ensembl; ENST00000439211; ENSP00000396308; ENSG00000228716. [P00374-1]
DR   Ensembl; ENST00000504396; ENSP00000421334; ENSG00000228716. [P00374-2]
DR   Ensembl; ENST00000505337; ENSP00000426474; ENSG00000228716. [P00374-1]
DR   GeneID; 1719; -.
DR   KEGG; hsa:1719; -.
DR   UCSC; uc003kgy.2; human. [P00374-1]
DR   CTD; 1719; -.
DR   DisGeNET; 1719; -.
DR   GeneCards; DHFR; -.
DR   HGNC; HGNC:2861; DHFR.
DR   HPA; CAB037129; -.
DR   HPA; HPA051465; -.
DR   MalaCards; DHFR; -.
DR   MIM; 126060; gene.
DR   MIM; 613839; phenotype.
DR   neXtProt; NX_P00374; -.
DR   OpenTargets; ENSG00000228716; -.
DR   Orphanet; 319651; Constitutional megaloblastic anemia with severe neurologic disease.
DR   PharmGKB; PA143; -.
DR   eggNOG; KOG1324; Eukaryota.
DR   eggNOG; COG0262; LUCA.
DR   GeneTree; ENSGT00390000010283; -.
DR   HOGENOM; HOG000040235; -.
DR   HOVERGEN; HBG000773; -.
DR   InParanoid; P00374; -.
DR   KO; K00287; -.
DR   OMA; NGIKYEY; -.
DR   OrthoDB; EOG091G0PRK; -.
DR   PhylomeDB; P00374; -.
DR   TreeFam; TF317636; -.
DR   BRENDA; 1.5.1.3; 2681.
DR   Reactome; R-HSA-113510; E2F mediated regulation of DNA replication.
DR   Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
DR   Reactome; R-HSA-196757; Metabolism of folate and pterines.
DR   Reactome; R-HSA-69205; G1/S-Specific Transcription.
DR   SABIO-RK; P00374; -.
DR   SIGNOR; P00374; -.
DR   UniPathway; UPA00077; UER00158.
DR   ChiTaRS; DHFR; human.
DR   EvolutionaryTrace; P00374; -.
DR   GeneWiki; Dihydrofolate_reductase; -.
DR   GenomeRNAi; 1719; -.
DR   PRO; PR:P00374; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000228716; -.
DR   CleanEx; HS_DHFR; -.
DR   ExpressionAtlas; P00374; baseline and differential.
DR   Genevisible; P00374; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0004146; F:dihydrofolate reductase activity; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0033560; F:folate reductase activity; TAS:Reactome.
DR   GO; GO:0005542; F:folic acid binding; IDA:BHF-UCL.
DR   GO; GO:0051870; F:methotrexate binding; IDA:BHF-UCL.
DR   GO; GO:0003729; F:mRNA binding; IDA:UniProtKB.
DR   GO; GO:0070402; F:NADPH binding; IDA:BHF-UCL.
DR   GO; GO:1990825; F:sequence-specific mRNA binding; IDA:CAFA.
DR   GO; GO:0000900; F:translation repressor activity, nucleic acid binding; IDA:CAFA.
DR   GO; GO:0031103; P:axon regeneration; ISS:BHF-UCL.
DR   GO; GO:0046452; P:dihydrofolate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0046655; P:folic acid metabolic process; ISS:BHF-UCL.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0006545; P:glycine biosynthetic process; IEA:InterPro.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:CAFA.
DR   GO; GO:0009165; P:nucleotide biosynthetic process; IEA:InterPro.
DR   GO; GO:0006730; P:one-carbon metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:BHF-UCL.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; ISS:BHF-UCL.
DR   GO; GO:2000121; P:regulation of removal of superoxide radicals; ISS:BHF-UCL.
DR   GO; GO:0000083; P:regulation of transcription involved in G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0031427; P:response to methotrexate; ISS:BHF-UCL.
DR   GO; GO:0006729; P:tetrahydrobiopterin biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0046654; P:tetrahydrofolate biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0046653; P:tetrahydrofolate metabolic process; IDA:UniProtKB.
DR   CDD; cd00209; DHFR; 1.
DR   Gene3D; 3.40.430.10; -; 1.
DR   InterPro; IPR012259; DHFR.
DR   InterPro; IPR024072; DHFR-like_dom.
DR   InterPro; IPR017925; DHFR_CS.
DR   InterPro; IPR001796; DHFR_dom.
DR   Pfam; PF00186; DHFR_1; 1.
DR   PRINTS; PR00070; DHFR.
DR   SUPFAM; SSF53597; SSF53597; 1.
DR   PROSITE; PS00075; DHFR_1; 1.
DR   PROSITE; PS51330; DHFR_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Disease mutation; Methotrexate resistance; Mitochondrion; NADP;
KW   One-carbon metabolism; Oxidoreductase; Reference proteome;
KW   RNA-binding.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P00376}.
FT   CHAIN         2    187       Dihydrofolate reductase.
FT                                /FTId=PRO_0000186362.
FT   DOMAIN        4    185       DHFR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00660}.
FT   NP_BIND      16     22       NADP. {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:16222560,
FT                                ECO:0000269|PubMed:19478082}.
FT   NP_BIND      55     57       NADP. {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:16222560,
FT                                ECO:0000269|PubMed:19478082}.
FT   NP_BIND      77     79       NADP. {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:16222560,
FT                                ECO:0000269|PubMed:19478082}.
FT   NP_BIND     117    124       NADP. {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:16222560,
FT                                ECO:0000269|PubMed:19478082}.
FT   REGION       31     36       Substrate binding.
FT                                {ECO:0000305|PubMed:2248959}.
FT   BINDING      10     10       NADP; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:16222560,
FT                                ECO:0000269|PubMed:19478082}.
FT   BINDING      65     65       Substrate. {ECO:0000305|PubMed:2248959}.
FT   BINDING      71     71       Substrate. {ECO:0000305|PubMed:2248959}.
FT   VAR_SEQ       1     52       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056352.
FT   VARIANT      80     80       L -> F (in DHFRD; dbSNP:rs387906619).
FT                                {ECO:0000269|PubMed:21310276}.
FT                                /FTId=VAR_065818.
FT   VARIANT     153    153       D -> V (in DHFRD; dbSNP:rs121913223).
FT                                {ECO:0000269|PubMed:21310277}.
FT                                /FTId=VAR_065819.
FT   MUTAGEN      23     23       L->F,W,Y: Decreases affinity for NADP and
FT                                dihydrofolate over 10-fold.
FT                                {ECO:0000269|PubMed:15681865,
FT                                ECO:0000269|PubMed:7890613}.
FT   MUTAGEN      23     23       L->R: Strongly decreased affinity for
FT                                methotrexate. Decreases catalytic rate
FT                                constant 200-fold. Decreases affinity for
FT                                NADP and dihydrofolate over 10-fold.
FT                                {ECO:0000269|PubMed:15681865,
FT                                ECO:0000269|PubMed:7890613}.
FT   MUTAGEN      32     32       F->R: Reduces catalytic rate 5-fold.
FT                                Reduces affinity for dihydrofolate 9-
FT                                fold; when associated with E-36.
FT                                {ECO:0000269|PubMed:19478082}.
FT   MUTAGEN      36     36       Q->E: Reduces catalytic rate 2-fold.
FT                                Reduces affinity for dihydrofolate 9-
FT                                fold; when associated with R-32.
FT                                {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:19196009,
FT                                ECO:0000269|PubMed:19478082}.
FT   MUTAGEN      36     36       Q->K: Increases affinity for
FT                                dihydrofolate about 3-fold. Reduces
FT                                affinity for NADPH about 3-fold.
FT                                {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:19196009,
FT                                ECO:0000269|PubMed:19478082}.
FT   MUTAGEN      36     36       Q->S: Increases affinity for
FT                                dihydrofolate about 2-fold. No effect on
FT                                affinity for NADPH.
FT                                {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:19196009,
FT                                ECO:0000269|PubMed:19478082}.
FT   MUTAGEN      65     65       N->F: Increases affinity for
FT                                dihydrofolate about 3-fold. No effect on
FT                                affinity for NADPH.
FT                                {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:19196009}.
FT   MUTAGEN      65     65       N->S: Increases affinity for
FT                                dihydrofolate about 15-fold. No effect on
FT                                affinity for NADPH.
FT                                {ECO:0000269|PubMed:15039552,
FT                                ECO:0000269|PubMed:19196009}.
FT   CONFLICT    113    113       V -> L (in Ref. 6; AAH70280).
FT                                {ECO:0000305}.
FT   STRAND        5     11       {ECO:0000244|PDB:1KMV}.
FT   STRAND       16     19       {ECO:0000244|PDB:1KMV}.
FT   STRAND       24     26       {ECO:0000244|PDB:5HVE}.
FT   HELIX        29     40       {ECO:0000244|PDB:1KMV}.
FT   STRAND       43     46       {ECO:0000244|PDB:5HQY}.
FT   STRAND       48     54       {ECO:0000244|PDB:1KMV}.
FT   HELIX        55     60       {ECO:0000244|PDB:1KMV}.
FT   HELIX        63     65       {ECO:0000244|PDB:1KMV}.
FT   STRAND       71     76       {ECO:0000244|PDB:1KMV}.
FT   STRAND       88     93       {ECO:0000244|PDB:1KMV}.
FT   HELIX        94    101       {ECO:0000244|PDB:1KMV}.
FT   TURN        104    109       {ECO:0000244|PDB:1KMV}.
FT   STRAND      110    115       {ECO:0000244|PDB:1KMV}.
FT   HELIX       119    126       {ECO:0000244|PDB:1KMV}.
FT   STRAND      128    130       {ECO:0000244|PDB:4M6K}.
FT   STRAND      132    141       {ECO:0000244|PDB:1KMV}.
FT   STRAND      146    148       {ECO:0000244|PDB:1KMV}.
FT   TURN        154    156       {ECO:0000244|PDB:1KMV}.
FT   STRAND      157    159       {ECO:0000244|PDB:1KMS}.
FT   STRAND      161    163       {ECO:0000244|PDB:3S7A}.
FT   STRAND      171    173       {ECO:0000244|PDB:1KMV}.
FT   STRAND      176    185       {ECO:0000244|PDB:1KMV}.
SQ   SEQUENCE   187 AA;  21453 MW;  EBDF3D1EC73E1566 CRC64;
     MVGSLNCIVA VSQNMGIGKN GDLPWPPLRN EFRYFQRMTT TSSVEGKQNL VIMGKKTWFS
     IPEKNRPLKG RINLVLSREL KEPPQGAHFL SRSLDDALKL TEQPELANKV DMVWIVGGSS
     VYKEAMNHPG HLKLFVTRIM QDFESDTFFP EIDLEKYKLL PEYPGVLSDV QEEKGIKYKF
     EVYEKND
//
